<code id='70E2CF1CF1'></code><style id='70E2CF1CF1'></style>
    • <acronym id='70E2CF1CF1'></acronym>
      <center id='70E2CF1CF1'><center id='70E2CF1CF1'><tfoot id='70E2CF1CF1'></tfoot></center><abbr id='70E2CF1CF1'><dir id='70E2CF1CF1'><tfoot id='70E2CF1CF1'></tfoot><noframes id='70E2CF1CF1'>

    • <optgroup id='70E2CF1CF1'><strike id='70E2CF1CF1'><sup id='70E2CF1CF1'></sup></strike><code id='70E2CF1CF1'></code></optgroup>
        1. <b id='70E2CF1CF1'><label id='70E2CF1CF1'><select id='70E2CF1CF1'><dt id='70E2CF1CF1'><span id='70E2CF1CF1'></span></dt></select></label></b><u id='70E2CF1CF1'></u>
          <i id='70E2CF1CF1'><strike id='70E2CF1CF1'><tt id='70E2CF1CF1'><pre id='70E2CF1CF1'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:14
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          PBMs drew scrutiny in House hearing — and so did pharma
          PBMs drew scrutiny in House hearing — and so did pharma

          Rep.JamesComer,chairoftheHouseOversightCommitteeKevinDietsch/GettyImagesWASHINGTON—Congresswantstore

          read more
          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more

          Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

          2:03FromlefttorightsplitshowsphotosofEmadShargi,MoradTahbazandSiamakNamaziHandoutAftermonthsofquietn